- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02301988
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
September 20, 2018 updated by: Genentech, Inc.
A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma.
The anticipated time on study treatment is 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
151
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lisboa, Portugal, 1099-023
- IPO de Lisboa; Servico de Oncologia Medica
-
Loures, Portugal, 2674-514
- Hospital Beatriz Angelo; Departamento de Oncologia
-
Porto, Portugal, 4200-072
- IPO do Porto; Servico de Oncologia Medica
-
-
-
-
-
Barcelona, Spain, 08908
- Institut Catala d Oncologia Hospital Duran i Reynals
-
Barcelona, Spain, 08035
- Hospital Univ Vall d'Hebron; Servicio de Oncologia
-
Caceres, Spain, 10003
- Hospital San Pedro De Alcantara; Servicio de Oncologia
-
Castellon, Spain, 12002
- Hospital Provincial de Castellon; Servicio de Oncologia
-
Girona, Spain, 17007
- Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre; Servicio de Oncologia
-
Madrid, Spain, 28040
- Hospital Universitario Clinico San Carlos
-
Madrid, Spain, 28050
- Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica
-
Madrid, Spain, 28040
- Fundacion Jimenez Diaz; Servicio de Oncologia
-
Madrid, Spain, 28033
- Centro Oncologico MD Anderson International Espana
-
Madrid, Spain, 28943
- Hospital Universitario de Fuenlabrada; Servicio de Oncologia
-
Madrid, Spain, 28223
- Hospital Quiron de Madrid; Servicio de Oncologia
-
Sevilla, Spain, 41013
- Hospital Virgen del Rocío
-
Valencia, Spain, 46010
- Hospital Clinico Universitario; Oncologia
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spain, 07014
- Hospital Universitario Son Espases
-
Palma de Mallorca, Islas Baleares, Spain, 07198
- Hospital Son Llatzer; Servicio de Oncologia
-
-
LA Coruña
-
Santiago de Compostela, LA Coruña, Spain, 15706
- Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
-
-
Lerida
-
Lleida, Lerida, Spain, 25198
- Hospital Universitari de Lleida Arnau de Vilanova
-
-
Madrid
-
Alcorcón (Madrid), Madrid, Spain, 28922
- Hospital Universitario Fundación Alcorcón
-
Mostoles, Madrid, Spain, 28933
- Hospital Rey Juan Carlos; Pharmacy
-
-
Malaga
-
Málaga, Malaga, Spain, 29011
- Hospital Regional Universitario Carlos Haya; hospital Materno Infantil, servicio de Farmacia
-
-
Sevilla
-
Seville, Sevilla, Spain, 41071
- Hospital Universitario Virgen Macarena
-
-
Tarragona
-
Reus, Tarragona, Spain, 43204
- Hospital Universitari Sant Joan de Reus; Servicio de Oncologia
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Arizona Oncology Associates, PC-CASA
-
-
California
-
Santa Barbara, California, United States, 93105
- Sansum Medical Clinic, Inc.
-
-
Colorado
-
Lakewood, Colorado, United States, 80228
- Rocky Mountain Cancer Center - Lakewood (West)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Danvers, Massachusetts, United States, 01923
- Mass General/North Shore Cancer
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Specialists; Oncology Hematology West, PC
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28208
- Carolinas Healthcare System
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Northwest Cancer Specialists - Portland (NE Hoyt St)
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Roper Bon Secours St. Francis Cancer Center
-
-
Texas
-
Austin, Texas, United States, 78705
- Texas Oncology
-
Austin, Texas, United States, 78731
- Texas Oncology Cancer Center
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Houston, Texas, United States, 77024
- Texas Oncology - Houston (Gessner)
-
Irving, Texas, United States, 75063
- Texas Oncology-Tyler
-
McAllen, Texas, United States, 78503
- South Texas Cancer Center - McAllen
-
-
Washington
-
Tacoma, Washington, United States, 98405
- NorthWest Medical Specialties, PLLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Premenopausal or postmenopausal women
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in largest diameter (cT1-3) by MRI
- Adequate hematologic and organ function within 14 days before the first study treatment
- Availability of tumor tissue from formalin-fixed, paraffin-embedded (FFPE) core biopsy of breast primary tumor
- For female participants of childbearing potential, agreement to use highly effective form(s) of contraception for the duration of the study and for at least 6 months after last dose of study treatment
Exclusion Criteria:
- Known human epidermal growth factor 2 (HER2)-positive, estrogen receptor (ER)-positive, or progesterone receptor (PgR)-positive breast cancer
- Any prior treatment for the current primary invasive breast cancer
- Participants with cT4 or cN3 stage breast tumors
- Metastatic (Stage IV) breast cancer
- Bilateral invasive breast cancer
- Multicentric breast cancer
- Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ipatasertib + Paclitaxel
Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
|
Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
Other Names:
Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.
|
Placebo Comparator: Placebo + Paclitaxel
Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
|
Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.
Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants)
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With pCR in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in Participants Who Have Phosphatase and Tensin Homolog [PTEN]-Low Tumors)
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis ypN0 in the AJCC Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With pCR in Breast as Defined by ypT0/Tis in the American Joint Committee on Cancer Staging System (in All Participants)
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With pCR in Breast as Defined by ypT0/Tis in the American Joint Committee on Cancer Staging System (in Participants Who Have PTEN-low Tumors)
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With Objective Tumor Response by Magnetic Resonance Imaging (MRI), As Assessed by Investigator Per the Modified Response Evaluation Criteria in Solid Tumors (RECIST) (in All Participants)
Time Frame: Screening up to disease progression or death (assessed at screening, pre-surgical visit [approximately Weeks 10-12], early termination visit [up to Week 16])
|
Objective tumor response (OR) was based on criteria related to changes in size of target lesions according to modified RECIST.
Target lesions were selected on the basis of their size (lesions with the longest diameter) as well as the feasibility of reproducible repeated measurements.
OR was the sum of complete response (CR) and partial response (PR).
CR: disappearance of all target lesions.
PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
|
Screening up to disease progression or death (assessed at screening, pre-surgical visit [approximately Weeks 10-12], early termination visit [up to Week 16])
|
Percentage of Participants With Objective Tumor Response by MRI, As Assessed by Investigator Per Modified RECIST (in Participants Who Have PTEN-low Tumors)
Time Frame: Screening up to disease progression or death (assessed at screening, pre-surgical visit [approximately Weeks 10-12], early termination visit [up to Week 16])
|
ORR was based on criteria related to changes in size of target lesions according to modified RECIST.
Target lesions were selected on the basis of their size (lesions with the longest diameter) as well as the feasibility of reproducible repeated measurements.
ORR was the sum of complete response (CR) and partial response (PR).
CR: disappearance of all target lesions.
PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
|
Screening up to disease progression or death (assessed at screening, pre-surgical visit [approximately Weeks 10-12], early termination visit [up to Week 16])
|
Percentage of Participants With pCR in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in Participants Who Are Akt Diagnostic Positive [Dx+])
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis ypN0 in the AJCC Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With pCR in Breast as Defined by ypT0/Tis in the American Joint Committee on Cancer Staging System (in Participants Who Are Akt Dx+)
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With pCR According to American Joint Committee on Cancer Staging System, by Breast Cancer Subtype
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast subtypes by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.
The intrinsic molecular subtypes of breast cancer included here are luminal A (LumA), Her-2, basal-like, normal and unknown.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With Response to Undergoing Breast Conserving Surgery (BCS) Among Participants With T2 or T3 Tumors
Time Frame: Surgery visit (at approximately Weeks 14 to 19)
|
After neoadjuvant treatment, the number of patients who is appropriate for breast conserving surgery is reported as a measure of efficacy of the treatment to shrink the tumor enough for patients to benefit from less aggressive surgical management.
Breast-conserving surgery was defined as removal of part of the breast tissue during surgery.
T2 or T3 in the AJCC Staging System were defined as follows: T2: tumor was more than 2 centimeter (cm) but no more than 5 cm across; T3: tumor was larger than 5 cm across.
|
Surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With Response to Conversion to BCS Among Participants With T2 or T3 Tumors
Time Frame: From screening to surgery visit (at approximately Weeks 14 to 19)
|
After neoadjuvant treatment, the number of patients who is appropriate for breast conserving surgery is reported as a measure of efficacy of the treatment to shrink the tumor enough for patients to benefit from less aggressive surgical management.
Breast-conserving surgery was defined as removal of part of the breast tissue during surgery.
T2 or T3 in the AJCC Staging System were defined as follows: T2: tumor was more than 2 centimeter (cm) but no more than 5 cm across; T3: tumor was larger than 5 cm across.
|
From screening to surgery visit (at approximately Weeks 14 to 19)
|
Percentage of Participants With Adverse Events
Time Frame: Screening up to Week 24
|
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as adverse events.
|
Screening up to Week 24
|
Plasma Concentrations of Ipatasertib on Day 1 and Day 8
Time Frame: 0.5 and 4 hours post dose on Day 1 of Cycle 1, 166 and 170 hours post dose from Day 1 of Cycle 1 (Cycle length = 28 days)
|
Plasma samples for pharmacokinetic characterization was collected at various timepoints in all participants.
|
0.5 and 4 hours post dose on Day 1 of Cycle 1, 166 and 170 hours post dose from Day 1 of Cycle 1 (Cycle length = 28 days)
|
Minimum Observed Plasma Concentration (Cmin) of Ipatasertib
Time Frame: 0.5 and 4 hours post dose on Day 1 of Cycle 1, 166 and 170 hours post dose from Day 1 of Cycle 1 (Cycle length = 28 days)
|
Plasma samples for pharmacokinetic characterization was collected on Day 1 and Day 8 in all participants.
|
0.5 and 4 hours post dose on Day 1 of Cycle 1, 166 and 170 hours post dose from Day 1 of Cycle 1 (Cycle length = 28 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 17, 2015
Primary Completion (Actual)
August 2, 2017
Study Completion (Actual)
August 2, 2017
Study Registration Dates
First Submitted
November 24, 2014
First Submitted That Met QC Criteria
November 24, 2014
First Posted (Estimate)
November 26, 2014
Study Record Updates
Last Update Posted (Actual)
October 17, 2018
Last Update Submitted That Met QC Criteria
September 20, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GO29505
- 2014-003029-16 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Ipatasertib
-
Genentech, Inc.CompletedHealthy VolunteerUnited States
-
Genentech, Inc.Completed
-
Hoffmann-La RocheCompleted
-
Genentech, Inc.CompletedHepatic InsufficiencyUnited States
-
Genentech, Inc.Completed
-
Institute of Cancer Research, United KingdomHoffmann-La RocheRecruitingSolid Tumor | Glioblastoma Multiforme | Prostate Cancer MetastaticUnited Kingdom
-
SOLTI Breast Cancer Research GroupRoche Pharma AGRecruitingMetastatic Breast CancerSpain
-
Jun Zhang, MD, PhDUniversity of Iowa; University of KentuckyRecruitingNSCLC Stage IV | NSCLC Stage IIIBUnited States
-
Hoffmann-La RocheRecruitingCancerKorea, Republic of, United Kingdom, Japan, Costa Rica, Belgium, Taiwan, Russian Federation, Mexico, Poland, France
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerIsrael, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more